Antibody Based Therapeutics
ADC development requires antibodies with genetically engineered Fc receptors that can achieve higher effector function. To fully evaluate function and efficacy, a model which contains the full human tumor microenvironment is critical.
WHY ARE HOLISTIC MODELS AND ASSAYS IMPORTANT?
Monoclonal antibodies (mAb), checkpoint inhibitors, Antibody Drug Conjugates (ADC), Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP) all require a model that contains the full immune complement as well as tumor microenvironment to be able to evaluate the ability of these molecules to penetrate tissue, overcome stromal interactions, and quantitatively determine mechanism of action and ultimately tumor cell death.
3D-EXplore’s use of fresh patient tumor tissue in conjunction with a suite of powerful and unique assays for penetration, tumor cell killing, phagocytosis and single cell proteogenomics provides a fully human solution for ADCCs and ADCPs during ADC development.
Capabilities
SCIENTIFIC DATA
Figure legend text:
Tumoroids were assessed for ADC-mediated tumor cell killing using pHrodo-labelled cetuximab. pHrodo labelled dyes fluoresce in an acidic environment, such as when the molecule is phagocytized by a cell and enters a lysosomal compartment.
High content confocal microscopy shows penetration and internalization into the lysosomal component of the pHrodo-labeled cetuximab in the tumoroid microenvironment. Merged images depict increased tumor cell death in response to ADC treatment compared to pHrodo-alone controls.
Related Resources
Browse our latest posters and presentations using Nilogen's fresh patient tumoroid technology.
